Literature DB >> 19894029

HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study.

E L M Barr1, A J Cameron, B Balkau, P Z Zimmet, T A Welborn, A M Tonkin, J E Shaw.   

Abstract

AIMS/HYPOTHESIS: We assessed whether the relationships between insulin sensitivity and all-cause mortality as well as fatal or non-fatal cardiovascular disease (CVD) events are independent of elevated blood glucose, high blood pressure, dyslipidaemia and body composition in individuals without diagnosed diabetes.
METHODS: Between 1999 and 2000, baseline fasting insulin, glucose and lipids, 2 h plasma glucose, HbA(1c), anthropometrics, blood pressure, medication use, smoking and history of CVD were collected from 8,533 adults aged >35 years from the population-based Australian Diabetes, Obesity and Lifestyle study. Insulin sensitivity was estimated by HOMA of insulin sensitivity (HOMA-%S). Deaths and fatal or non-fatal CVD events were ascertained through linkage to the National Death Index and medical records adjudication.
RESULTS: After a median of 5.0 years there were 277 deaths and 225 CVD events. HOMA-%S was not associated with all-cause mortality. Compared with the most insulin-sensitive quintile, the combined fatal or non-fatal CVD HR (95% CI) for quintiles of decreasing HOMA-%S were 1.1 (0.6-1.9), 1.4 (0.9-2.3), 1.6 (1.0-2.5) and 2.0 (1.3-3.1), adjusting for age and sex. Smoking, CVD history, hypertension, lipid-lowering medication, total cholesterol and waist-to-hip ratio moderately attenuated this relationship. However, the association was rendered non-significant by adding HDL. Fasting plasma glucose, but not HOMA-%S significantly improved the prediction of CVD, beyond that seen with other risk factors. CONCLUSIONS/
INTERPRETATION: In this cohort, HOMA-%S showed no association with all-cause mortality and only a modest association with CVD events, largely explained by its association with HDL. Fasting plasma glucose was a better predictor of CVD than HOMA-%S.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19894029     DOI: 10.1007/s00125-009-1588-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  44 in total

1.  Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.

Authors:  James B Meigs; Martin K Rutter; Lisa M Sullivan; Caroline S Fox; Ralph B D'Agostino; Peter W F Wilson
Journal:  Diabetes Care       Date:  2007-01-26       Impact factor: 19.112

2.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

3.  Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes.

Authors:  M P Hermans; J C Levy; R J Morris; R C Turner
Journal:  Diabetologia       Date:  1999-06       Impact factor: 10.122

4.  Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study.

Authors:  Martin K Rutter; James B Meigs; Lisa M Sullivan; Ralph B D'Agostino; Peter W Wilson
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

5.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

Authors: 
Journal:  Arch Intern Med       Date:  2001-02-12

6.  Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).

Authors:  Elizabeth L M Barr; Paul Z Zimmet; Timothy A Welborn; Damien Jolley; Dianna J Magliano; David W Dunstan; Adrian J Cameron; Terry Dwyer; Hugh R Taylor; Andrew M Tonkin; Tien Y Wong; John McNeil; Jonathan E Shaw
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

7.  Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab).

Authors:  Esther M Briganti; Jonathan E Shaw; Steven J Chadban; Paul Z Zimmet; Timothy A Welborn; John J McNeil; Robert C Atkins
Journal:  Med J Aust       Date:  2003-08-04       Impact factor: 7.738

8.  Hyperinsulinaemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmö Preventive Project.

Authors:  P Nilsson; J-A Nilsson; B Hedblad; K-F Eriksson; G Berglund
Journal:  J Intern Med       Date:  2003-02       Impact factor: 8.989

Review 9.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

Authors:  S E Kahn
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122

10.  Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women.

Authors:  Debbie A Lawlor; Abigail Fraser; Shah Ebrahim; George Davey Smith
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

View more
  15 in total

1.  Dysmetabolic Signals in "Metabolically Healthy" Obesity.

Authors:  Peter Manu; Constantin Ionescu-Tirgoviste; James Tsang; Barbara A Napolitano; Martin L Lesser; Christoph U Correll
Journal:  Obes Res Clin Pract       Date:  2012-01       Impact factor: 2.288

2.  Homeostasis model assessment of insulin resistance and the risk of cardiovascular events in middle-aged non-diabetic Japanese men.

Authors:  K Nakamura; M Sakurai; K Miura; Y Morikawa; M Ishizaki; K Yoshita; T Kido; Y Naruse; H Nakagawa
Journal:  Diabetologia       Date:  2010-05-26       Impact factor: 10.122

3.  The association between insulin sensitivity indices, ECG findings and mortality: a 40-year cohort study.

Authors:  Yonatan Moshkovits; David Rott; Angela Chetrit; Rachel Dankner
Journal:  Cardiovasc Diabetol       Date:  2021-05-06       Impact factor: 9.951

4.  Hypertension and diabetes in obesity.

Authors:  Kazuko Masuo; Michael L Tuck; Gavin W Lambert
Journal:  Int J Hypertens       Date:  2011-06-20       Impact factor: 2.420

5.  Transcriptomic alterations in the heart of non-obese type 2 diabetic Goto-Kakizaki rats.

Authors:  Márta Sárközy; Gergő Szűcs; Veronika Fekete; Márton Pipicz; Katalin Éder; Renáta Gáspár; Andrea Sója; Judit Pipis; Péter Ferdinandy; Csaba Csonka; Tamás Csont
Journal:  Cardiovasc Diabetol       Date:  2016-08-05       Impact factor: 9.951

6.  External Validation of a Tool Predicting 7-Year Risk of Developing Cardiovascular Disease, Type 2 Diabetes or Chronic Kidney Disease.

Authors:  Simone P Rauh; Femke Rutters; Amber A W A van der Heijden; Thomas Luimes; Marjan Alssema; Martijn W Heymans; Dianna J Magliano; Jonathan E Shaw; Joline W Beulens; Jacqueline M Dekker
Journal:  J Gen Intern Med       Date:  2017-12-04       Impact factor: 5.128

7.  Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial.

Authors:  Suzanne J Grant; Dennis Hsu-Tung Chang; Jianxun Liu; Vincent Wong; Hosen Kiat; Alan Bensoussan
Journal:  BMC Complement Altern Med       Date:  2013-05-14       Impact factor: 3.659

8.  Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats.

Authors:  Márta Sárközy; Agnes Zvara; Nóra Gyémánt; Veronika Fekete; Gabriella F Kocsis; Judit Pipis; Gergő Szűcs; Csaba Csonka; László G Puskás; Péter Ferdinandy; Tamás Csont
Journal:  Cardiovasc Diabetol       Date:  2013-01-15       Impact factor: 9.951

9.  Cardio-metabolic risk factors and prehypertension in persons without diabetes, hypertension, and cardiovascular disease.

Authors:  Peggy P C Chiang; Ecosse L Lamoureux; Anoop Shankar; E Shyong Tai; Tien Y Wong; Charumathi Sabanayagam
Journal:  BMC Public Health       Date:  2013-08-07       Impact factor: 3.295

Review 10.  Ceramide and Sphingosine 1-Phosphate in Liver Diseases.

Authors:  Woo-Jae Park; Jae-Hwi Song; Goon-Tae Kim; Tae-Sik Park
Journal:  Mol Cells       Date:  2020-05-31       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.